Allergan left all options on the table in terms of the types of deals that the ever-growing company will pursue with its $36bn in after-tax proceeds from the $40.5bn sale of its generics business to Teva Pharmaceutical Industries.
Some of the money will pay down debt related to past mergers and acquisitions, but Allergan plans to spend a...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?